Profile
David Howat worked as a Director of Preclinical Development at Nicox SA, a Chief Development Officer at Evgen Pharma Plc and Evgen Ltd., Head of Project Management at K.S.
Biomedix Holdings Plc, and a Team Leader at Celltech Chiroscience Plc.
Former positions of David Howat
| Companies | Position | End |
|---|---|---|
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Develops novel glucosinolate based products for the prevention and treatment of human disease | Director/Board Member | 20/10/2015 |
| THERACRYF PLC | Corporate Officer/Principal | - |
K.S. Biomedix Holdings Plc
K.S. Biomedix Holdings Plc Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products | Corporate Officer/Principal | - |
| NICOX SA | Corporate Officer/Principal | - |
Celltech Chiroscience Plc
Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Research-based pharmaceutical group | Corporate Officer/Principal | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Evgen Pharma Plc
Evgen Pharma Plc Medical/Nursing ServicesHealth Services Engages in the development of pharmaceutical products and focus on cancer & neurological disease | Health Services |
Nicox SA
Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
K.S. Biomedix Holdings Plc
K.S. Biomedix Holdings Plc Pharmaceuticals: MajorHealth Technology Researches and develops biopharmaceutical products | Health Technology |
Celltech Chiroscience Plc
Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Research-based pharmaceutical group | Commercial Services |
Evgen Ltd.
Evgen Ltd. Medical/Nursing ServicesHealth Services Develops novel glucosinolate based products for the prevention and treatment of human disease | Health Services |
- Stock Market
- Insiders
- David Howat
















